Fate Therapeutics — Third Quarter 2026 Earnings Summary

Fate Therapeutics reported a net loss of $30.7 million for the third quarter of 2026, with total operating expenses of $32.2 million and cash, cash equivalents, and investments totaling $139.1 million as of September 30, 2026. The company received a $15.0 million grant from the California Institute for Regenerative Medicine to support its RECLAIM-LN Phase 2 trial for lupus nephritis, which utilizes the FT819 product candidate. Preliminary Phase 1 data presented at ASN Kidney Week 2026 demonstrated a 100% renal response rate in patients treated with FT819 and a bendamustine conditioning regimen. Additionally, the company activated multiple clinical sites for the COMPLETE basket trial of FT839, a dual CD19/CD38 targeting CAR T-cell product, and expects to extend its cash runway to mid-2028.